Low-density lipoprotein receptor-related protein 8
| View/Edit Human | View/Edit Mouse |
Low-density lipoprotein receptor-related protein 8 (LRP8), also known as apolipoprotein E receptor 2 (ApoER2), is a protein that in humans is encoded by the LRP8 gene.[3][4][5] ApoER2 is a cell surface receptor that is part of the low-density lipoprotein receptor family. These receptors function in signal transduction and endocytosis of specific ligands. Through interactions with one of its ligands, reelin, ApoER2 plays an important role in embryonic neuronal migration and postnatal long-term potentiation. Another LDL family receptor, VLDLR, also interacts with reelin, and together these two receptors influence brain development and function. Decreased expression of ApoER2 is associated with certain neurological diseases.[6]
Structure
ApoER2 is a protein made up of 870 amino acids. It is separated into a ligand binding domain of eight ligand binding regions, an EGF-like domain containing three cysteine-rich repeats, an O-linked glycosylation domain of 89 amino acids, a transmembrane domain of 24 amino acids, and a cytoplasmic domain of 115 amino acids, including an NPXY motif.[7]
Each letter in the NPXY motif represents a certain amino acid where N is arginine, P is proline, X is any amino acid, and Y is tyrosine.
Cytoplasmic tail
All LDL receptor family proteins contain a cytoplasmic tail with at least one NPXY motif. This motif is important for binding intracellular adapter proteins and endocytosis. ApoER2 is distinct from most other members of the LDL family of receptors due to a unique insert on its cytoplasmic tail. In ApoER2, there is a proline-rich 59 amino acid insert encoded by the alternatively spliced exon 19. This insert allows for protein interactions that are unable to occur with other LDL receptors. It binds the PSD-95 adapter protein, cross-linking ApoER2 and the NMDA receptors during the process of long-term potentiation, and is also bound specifically by JIP-2, an important interaction in the JNK signalling pathway. It is also speculated that this insert may diminish the function of ApoER2 in lipoprotein endocytosis by somehow disrupting the NPXY motif.[6][7]
Function
Reelin/Dab1 signalling pathway
ApoER2 plays a critical role as a receptor in the reelin signalling pathway, which is important for brain development and postnatal function of the brain.[8] This pathway specifically affects cortical migration and long-term potentiation.
Cortical migration
In development, reelin is secreted by Cajal-Retzius cells. Reelin acts as an extracellular ligand binding to ApoER2 and VLDLR on migrating neurons. A specific lysine residue on reelin binds to the first repeat on the ligand binding domain of ApoER2. This interaction with the two receptors activates intracellular processes that begin with the phosphorylation of Dab1, a tyrosine kinase phosphorylated protein which is encoded by the DAB1 gene. This protein associates with the NPXY motifs on the intracellular tails of ApoER2 and VLDLR.[9] Upon reelin binding, Dab1 is phosphorylated by two tyrosine kinases, Fyn and Src. The phosphorylated Dab1 then causes further activation of these two kinases and others, including a phosphatidylinositol-3-kinase (PI3K). PI3K activation leads to inhibitory phosphorylation of the tau kinase glycogen synthase kinase 3 beta (GSK3B), which alters the activity of tau protein, a protein involved in stabilizing microtubules. This transduction is combined with the activation of other pathways that influence the cytoskeletal rearrangement necessary for proper cortical cell migration.[6][8]
The result of proper neuronal migration through the cortical plate (CP) is an inside-out arrangement of neurons, where the younger neurons migrate past the older neurons to their proper locations. Studies in reeler mutant mice show that knocking out the reeler gene results in aberrant migration as well as outside-in layering, in which younger neurons are unable to travel past the older ones. Such abnormal layering is also seen in VLDLR−apoER2− and dab1- mutants, indicating the importance of this entire pathway in cortical migration of the developing embryo.[9]
There is some confusion as to the exact function of the reelin-signalling pathway in the process of cortical migration. Some studies have shown that reelin release is necessary for the initiation of cell movement to its proper location, whereas others have shown that it is part of the process of terminating migration. These conflicting results have led researchers to speculate that it plays a role in both processes through interactions with different molecules at different stages of neuronal migration.[9]
Long-term potentiation
After development, reelin is secreted in the cortex and hippocampus by gamma-aminobutyric acid-ergic interneurons. Through binding of ApoER2 in the hippocampus, it plays a role in the NMDA receptor activation that is required for long-term potentiation, a mechanism by which two neurons gain a stronger, longer-lasting transmission due to simultaneous firing. The increased synaptic plasticity associated with this process is essential in development of memory and spatial learning.[6] Studies with mice have shown less expression of ApoER2 leads to impaired spatial learning, fear conditioned learning, and a mild disruption to the hippocampus.[8]
In the hippocampus, ApoER2 is complexed with NMDA receptors through the PSD-95 adapter protein. When reelin binds ApoER2, it initiates tyrosine phosphorylation of NMDA receptors. This occurs through Dab-1 activation of Src family kinases, which have been shown to play a role in regulating synaptic plasticity. VLDLR also acts as a receptor coupled to ApoER2 as it does during development, but its role is not well-understood.[8] ApoER2 plays a more important role in this process, most likely due to its ability to bind the PSD-95 adapter protein through the 59 amino acid insert on its cytoplasmic tail. Studies with mice have shown that knocking out ApoER2 or just the alternatively spliced exon 19 causes a much greater impairment of LTP than knocking out VLDLR.[7]
Other interacting proteins
Apolipoprotein E
Apolipoprotein E (ApoE) plays an important role in phospholipid and cholesterol homeostasis. After binding ApoER2, ApoE is taken up into the cell and may remain in the intracellular space, be shipped to the cell surface, or be degraded. ApoE binding leads to the cleavage of ApoER2 into secreted proteins by the actions of the plasma membrane protein gamma secretase. ApoE may be the signalling ligand responsible for ApoER2's role in modulating the JNK signalling pathway.[7][8]
FE65
FE65 is an intracellular protein that binds to the NPXY motif of ApoER2 and plays a role in linking other proteins, such as amyloid precursor protein, to ApoER2. This protein aids in a cell's migrational functions. Knockout studies of FE65 have shown a link to lissencephaly.[7]
JIP1 and JIP2
JIP1 and JIP2 are involved in the JNK-signaling pathway and interact with exon 19 of ApoER2. For JIP2, interaction with exon 19 of ApoER2 is through the PID domain. This interaction has led researchers to believe that ApoER2 is involved in many interactions at the surface of cells.[7]
Selenoprotein P
Selenoprotein P transports the trace element selenium from the liver to the testes and brain, and binds to ApoER2 in these areas. ApoER2 functions to internalize this complex to maintain normal levels of selenium in these cells.[7] Selenium is necessary in the testes for proper spermatozoa development. Mice that have had their ApoER2 or Selenoprotein P expression knocked out show impaired spermatozoa development and decreased fertility. In the brain, deficiencies in selenium and selenium uptake mechanisms result in brain damage.[10]
Thrombospondin and F-spondin
Thrombospondin is a protein found in the extracellular matrix that competes with reelin to bind ApoER2. It is involved with cell-to-cell communication and migration of neurons, and causes the activation of Dab1. F-spondin is a secreted protein that also binds ApoER2 and leads to phosphorylation of Dab1.[7]
Clinical significance
Alzheimer's disease
Alzheimer's disease is the most common form of dementia, and studies have shown that manipulation of pathways involving LRP8/ApoER2 can lead to the disease. Certain alleles, such as apoe, app, ps1 and ps2, may lead to being genetically predisposed to the disease.[11] A decrease in LRP8 expression is observed in patients with Alzheimer’s disease. An example of a decrease in expression of LRP8 is when gamma secretase cleaves LRP8 as well as the ligand amyloid precursor protein (APP). The degradation products control transcription factors, which lead to the expression of a tau protein. The cascade dysfunction caused by the altered gene expression may be implicated with Alzheimer’s disease.[12]
The presence of amyloid beta (Aβ) protein deposits in neuronal extracellular space is one of the hallmarks of Alzheimer’s disease. The role of ApoER2 in Alzheimer’s disease is relevant, yet incompletely understood. New evidence suggests ApoER2 plays a major role in the regulation of amyloid-β formation in the brain. The amyloid-β peptide is derived from the cleavage of APP by gamma secretase.[13] ApoER2 works to reduce APP trafficking by altering break down. This interaction decreases APP endocytosis leading to an increase in amyloid-β production. In addition, the expression of ApoER2 within intracellular compartments leads to increased gamma secretase activity, a protease which works to cleave APP into Aβ.[13][14]
ApoER2 splice variants can act as a receptor for alpha-2-macroglobulin which can have a role in clearance of alpha-2-macroglobulin/proteinase complex. Proteases may play a role in synaptic plasticity balancing proteolytic activity and inhibition, which is controlled by proteolytic inhibitors such as alpha-2-macroglobulin. Studies have shown that a high presence of alpha-2-macroglobulin is present in the neuritic plaques in many Alzheimer patients. Isolation of cDNA encoding proteins associated with Aβ was used to discover alpha-2-macroglobulin. These discoveries may link alpha-2-macroglobulin and its receptors, one of them being ApoER2, to Alzheimer’s disease.[15]
ApoER2 interaction with reelin and ApoE has implications with Alzheimer’s disease. Binding of reelin to ApoER2 leads to cascade of signals that modulate NMDA receptor functions. ApoE competes with reelin in binding to ApoER2 resulting in weakened reelin signaling. Reduced reelin signaling leads to impaired plasticity in neurons and increases in the phosphorylation of tau protein, which is a microtubule stabilizing protein that is abundant in the Central Nervous System (CNS), producing neurofibrillary tangles which are implicated in Alzheimer’s disease.[16]
Antiphospholipid syndrome
Antiphospholipid syndrome is an autoimmune disease characterized by thrombosis and complications during pregnancy, often leading to fetal death. It is caused by the presence of antibodies against anionic phospholipids and β2-glycoprotein I (β2GPI). The anti-β2GPI antibodies are most prevalent in causing the symptoms of the disease. When bound by an antibody, β2GPI begins to interact with monocytes, endothelial cells, and platelets. ApoER2 is thought to play a key role in the process of platelet binding. β2GPI has the proper binding site for interaction with ApoER2 and other LDL family receptors, and it is speculated that the antibody/β2GPI complexes interact with ApoER2 on platelets. This causes the phosphorylation of a p38MAPkinase, resulting in the production of thromboxane A2. Thromboxane A2 functions to activate more platelets, and this leads to a greater chance for blood clots to form. There is also speculation that the antibody/β2GPI complexes sensitize other cell types through various LDL family receptors to lead to less common symptoms other than thrombosis.[17]
Major depressive disorder
Reduced expression of ApoER2 in peripheral blood lymphocytes can contribute to major depressive disorder (MDD) in some patients. Major depressive disorder is the most common psychiatric disorder, where people show symptoms of low self-esteem and a loss of interest in pleasure. By studying the levels of ApoER2 mRNA, low levels of ApoER2 were discovered. Results from experiments have shown that this could be because of transcriptional alterations in lymphocytes. However, low levels of ApoER2 do not appear to correlate with the severity or duration of the disease. It only aids as a trait marker in identification of the disease. The impact of the low levels of ApoER2 mRNA function relating to the disease remains unknown.[18]
References
- ↑ "Human PubMed Reference:".
- ↑ "Mouse PubMed Reference:".
- ↑ Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T (Jun 1996). "Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain". J Biol Chem. 271 (14): 8373–80. doi:10.1074/jbc.271.14.8373. PMID 8626535.
- ↑ Kim DH, Magoori K, Inoue TR, Mao CC, Kim HJ, Suzuki H, Fujita T, Endo Y, Saeki S, Yamamoto TT (May 1997). "Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene". J Biol Chem. 272 (13): 8498–504. doi:10.1074/jbc.272.13.8498. PMID 9079678.
- ↑ "Entrez Gene: LRP8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor".
- 1 2 3 4 Myant NB (February 2010). "Reelin and apolipoprotein E receptor 2 in the embryonic and mature brain: effects of an evolutionary change in the apoER2 gene". Proc. Biol. Sci. 277 (1680): 345–51. doi:10.1098/rspb.2009.1412. PMC 2842643
. PMID 19846452. - 1 2 3 4 5 6 7 8 Reddy SS, Connor TE, Weeber EJ, Rebeck W (2011). "Similarities and differences in structure, expression, and functions of VLDLR and ApoER2". Mol Neurodegener. 6: 30. doi:10.1186/1750-1326-6-30. PMC 3113299. PMID 21554715.
- 1 2 3 4 5 Qiu S, Korwek KM, Weeber EJ (January 2006). "A fresh look at an ancient receptor family: emerging roles for low density lipoprotein receptors in synaptic plasticity and memory formation". Neurobiol Learn Mem. 85 (1): 16–29. doi:10.1016/j.nlm.2005.08.009. PMID 16198608.
- 1 2 3 Honda T, Kobayashi K, Mikoshiba K, Nakajima K (July 2011). "Regulation of cortical neuron migration by the reelin signaling pathway". Neurochem. Res. 36 (7): 1270–9. doi:10.1007/s11064-011-0407-4. PMID 21253854.
- ↑ Burk RF, Hill KE (November 2009). "Selenoprotein P-expression, functions, and roles in mammals". Biochim. Biophys. Acta. 1790 (11): 1441–7. doi:10.1016/j.bbagen.2009.03.026. PMC 2763998. PMID 19345254.
- ↑ Cooper JA, Howell BW (June 1999). "Lipoprotein receptors: signaling functions in the brain?". Cell. 97 (6): 671–4. doi:10.1016/S0092-8674(00)80778-3. PMID 10380917.
- ↑ Carter CJ (January 2007). "Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis". Neurochem. Int. 50 (1): 12–38. doi:10.1016/j.neuint.2006.07.007. PMID 16973241.
- 1 2 Herz J (June 2009). "Apolipoprotein E receptors in the nervous system". Curr. Opin. Lipidol. 20 (3): 190–6. doi:10.1097/MOL.0b013e32832d3a10. PMC 2848396. PMID 19433918.
- ↑ Marzolo MP, Bu G (April 2009). "Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease". Semin. Cell Dev. Biol. 20 (2): 191–200. doi:10.1016/j.semcdb.2008.10.005. PMC 2691858. PMID 19041409.
- ↑ Nimpf J, Schneider WJ (December 2000). "From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2". Biochim. Biophys. Acta. 1529 (1-3): 287–98. doi:10.1016/S1388-1981(00)00155-4. PMID 11111096.
- ↑ Chin J, Roberson ED, Mucke L (2008). "Molecular Aspects of Memory Dysfunction in Alzheimer's Disease". Learning and Memory: A Comprehensive Reference. 4 (15): 245–293. doi:10.1016/B978-012370509-9.00015-2.
- ↑ de Groot PG, Derksen RH (August 2005). "Pathophysiology of the antiphospholipid syndrome". J. Thromb. Haemost. 3 (8): 1854–60. doi:10.1111/j.1538-7836.2005.01359.x. PMID 16102052.
- ↑ Suzuki K, Iwata Y, Matsuzaki H, Anitha A, Suda S, Iwata K, Shinmura C, Kameno Y, Tsuchiya KJ, Nakamura K, Takei N, Mori N (August 2010). "Reduced expression of apolipoprotein E receptor type 2 in peripheral blood lymphocytes from patients with major depressive disorder". Prog. Neuropsychopharmacol. Biol. Psychiatry. 34 (6): 1007–10. doi:10.1016/j.pnpbp.2010.05.014. PMID 20493228.
Further reading
- Clatworthy AE, Stockinger W, Christie RH, Schneider WJ, Nimpf J, Hyman BT, Rebeck GW (1999). "Expression and alternate splicing of apolipoprotein E receptor 2 in brain". Neuroscience. 90 (3): 903–11. doi:10.1016/S0306-4522(98)00489-8. PMID 10218790.
- Sun XM, Soutar AK (1999). "Expression in vitro of alternatively spliced variants of the messenger RNA for human apolipoprotein E receptor-2 identified in human tissues by ribonuclease protection assays". Eur. J. Biochem. 262 (1): 230–9. doi:10.1046/j.1432-1327.1999.00394.x. PMID 10231386.
- Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J (1999). "Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2". Cell. 97 (6): 689–701. doi:10.1016/S0092-8674(00)80782-5. PMID 10380922.
- Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS (1999). "Identification and characterization of LRP8 (apoER2) in human blood platelets". J. Lipid Res. 40 (10): 1925–30. PMID 10508213.
- D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T (1999). "Reelin is a ligand for lipoprotein receptors". Neuron. 24 (2): 471–9. doi:10.1016/S0896-6273(00)80860-0. PMID 10571240.
- Korschineck I, Ziegler S, Breuss J, Lang I, Lorenz M, Kaun C, Ambros PF, Binder BR (2001). "Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue". J. Biol. Chem. 276 (16): 13192–7. doi:10.1074/jbc.M011795200. PMID 11152697.
- Riddell DR, Sun XM, Stannard AK, Soutar AK, Owen JS (2001). "Localization of apolipoprotein E receptor 2 to caveolae in the plasma membrane". J. Lipid Res. 42 (6): 998–1002. PMID 11369809.
- Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J (2002). "Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning". J. Biol. Chem. 277 (42): 39944–52. doi:10.1074/jbc.M205147200. PMID 12167620.
- Stockinger W, Sailler B, Strasser V, Recheis B, Fasching D, Kahr L, Schneider WJ, Nimpf J (2002). "The PX-domain protein SNX17 interacts with members of the LDL receptor family and modulates endocytosis of the LDL receptor". EMBO J. 21 (16): 4259–67. doi:10.1093/emboj/cdf435. PMC 126172. PMID 12169628.
- Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC (2003). "Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease". Neurosci. Lett. 332 (3): 216–8. doi:10.1016/S0304-3940(02)00942-4. PMID 12399018.
- Koch S, Strasser V, Hauser C, Fasching D, Brandes C, Bajari TM, Schneider WJ, Nimpf J (2003). "A secreted soluble form of ApoE receptor 2 acts as a dominant-negative receptor and inhibits reelin signaling". EMBO J. 21 (22): 5996–6004. doi:10.1093/emboj/cdf599. PMC 137191. PMID 12426372.
- Sun XM, Soutar AK (2003). "The transmembrane domain and PXXP motifs of ApoE receptor 2 exclude it from carrying out clathrin-mediated endocytosis". J. Biol. Chem. 278 (22): 19926–32. doi:10.1074/jbc.M302047200. PMID 12621059.
- Benhayon D, Magdaleno S, Curran T (2003). "Binding of purified reelin to ApoER2 and VLDLR mediates tyrosine phosphorylation of Disabled-1". Brain Res. Mol. Brain Res. 112 (1–2): 33–45. doi:10.1016/S0169-328X(03)00032-9. PMID 12670700.
- Sacre SM, Stannard AK, Owen JS (2003). "Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells". FEBS Lett. 540 (1–3): 181–7. doi:10.1016/S0014-5793(03)00261-8. PMID 12681505.
- Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG (2003). "Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'". J. Biol. Chem. 278 (36): 33831–8. doi:10.1074/jbc.M212655200. PMID 12807892.
- Bajari TM, Strasser V, Nimpf J, Schneider WJ (2003). "A model for modulation of leptin activity by association with clusterin". FASEB J. 17 (11): 1505–7. doi:10.1096/fj.02-1106fje. PMID 12824284.
- May P, Bock HH, Nimpf J, Herz J (2003). "Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase". J. Biol. Chem. 278 (39): 37386–92. doi:10.1074/jbc.M305858200. PMID 12871934.
External links